| [1] |
International Diabetes Federation. IDF General 2016[EB/OL].
URL
|
| [2] |
中华医学会糖尿病学分会．中国2型糖尿病防治指南(2013年版)[J]．中华糖尿病杂志，2014，6(7):447-497.
|
| [3] |
Yang LL, Shao J, Bian YY, et al. Prevalence of type 2 diabetes mellitus among inland residents in China (2000-2014): a meta-analysis [J]. J Diabetes Investig, 2016, 7(6):854-852.
|
| [4] |
Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes [J]. Diabetes, 2009, 58(7):1651-1658.
|
| [5] |
Yamagishi S, Matsui T, Fukami K. Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk [J]. Rejuvenation Res, 2015, 18(1):48-56.
|
| [6] |
陈玉萍，吴云皓，许慧琴．糖基化终末产物致糖尿病肾病足细胞损伤的信号通路机制研究进展[J]．医学综述，2016，22(16):3206-3209.
|
| [7] |
顾天菊，王清．糖基化终末产物与糖尿病肾病关系研究进展[J]．中国实验诊断学，2017，21(2):364-367.
|
| [8] |
农伟虎，许慧琴. 糖基化终末产物与糖尿病肾病产生机制的研究成果[J]．南京中医药大学学报，2012，28(2):195-197.
|
| [9] |
Kerkeni M, Saidi A, Bozidi H, et al. Pentosidine as a biomarker for microvascular complication in type 2 diabetic patients [J]．Diab Vasc Dis Res, 2013, 10(3):239-245.
|
| [10] |
Ojima A, Matsui T, Nishino Y, et al. Empagliflozin, an inhibitor of sodium-glucose cotransporter exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis [J]. Horm Metab Res, 2015, 47(9):686-692.
|
| [11] |
Geraldes P, King GL. Activation of protein kinase C isoforms and its impact on diabetic complications [J]. Circ Res, 2010, 106(8):1319-1331.
|
| [12] |
Tsugawa T, Shinohara R, Nagasaka A, et al. Alteration of urinary sorbitol excretion in WBN-kob diabetic rats treatment with an aldose reductase inhibitor [J]. J Endocrinol, 2004, 181(3):429-435.
|
| [13] |
Chen CL, Tang Y, Zheng Z, et al. Advanced glycation end-products the renin-angiotensin-system through the RAGE/PI3-K signaling pathway in podocytes [J]. Clin Invest Med, 2012, 35(5):E282.
|
| [14] |
Fukami K, Yamigashi SI, Kaifu K, et al. Telmisartan inhibits AGE-induced podocyte damage and detachment [J]. Microvasc Res, 2013, 88:79-83.
|
| [15] |
Hasegawa G, Nakano K, Sawada M, et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy [J]. Kid Inv, 1991, 40(6):1007-1012.
|
| [16] |
刘晓敏，董哲毅，陈香美．表观遗传修饰在糖尿病肾病发病机制中的作用研究进展[J/CD]．中华肾病研究电子杂志，2016，5(4):177-181.
|
| [17] |
Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, et al. Inflammatory cytokines in diabetic nephropathy [J]. J Diabetes Res, 2015, 2(15):1-9.
|
| [18] |
Lim AK, Tesch GH. Inflammation in diabetic nephropathy [J]. Mediators Inflamm, 2012, 8(21):1-12.
|
| [19] |
Maeda Y, Inoguchi T, Takei R, et al. Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters [J]. Am J Physiol Renal Physiol, 2013, 299(6):F1328-F1338.
|
| [20] |
Gorin Y, Wauquie F. Upstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease [J]. Mol Cells, 2015, 38(4):285-296.
|
| [21] |
Brosius FC, Coward RJ. Podocytes signaling pathways and vascular factors in diabetic kidney disease [J]. Adv Chronic Kidney Dis, 2014, 21(3):304-310.
|
| [22] |
Martínez-Castelao A, Navarro-González JF, Górriz JL, et al. The concept of diabetic nephropathy have changed in recent years [J]. J Clin MED, 2015, 4(6):1207-1216.
|
| [23] |
Rizvi S, Raza ST, Mahdi F. Association of genetic variants with diabetic nephropathy [J]. World J Diabetes, 2014, 5(6):809-816.
|
| [24] |
Palmer ND, Freedmen BI. Insight of the genetic architecture of diabetic nephropathy [J]. Curr Diab Rep, 2012, 12(4):423-431.
|
| [25] |
Liu R, Lee K, He JC. Genetics and epigentics of diabetic nephropathy [J]. Kidney Dis, 2015, 1(1):42-51.
|
| [26] |
Mogensen CE, Christensen CK, Vittinghus E, et al. The stages in diabetic renal disease with emphasis on the stage of incipient diabetic nephropathy [J]. Diabetes, 1983, 32(S2):64-78.
|
| [27] |
Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA consensus conference [J]. Diabetes Care, 2014, 37(10):2864-2883.
|
| [28] |
中华医学会糖尿病学分会．中国2型糖尿病防治指南(2013年版)[J]．中国医学前沿杂志(电子版)，2015，7(3):26-89.
|
| [29] |
韩雅纯，孙林．糖尿病肾病治疗的循证医学新进展[J/CD]．中华肾病研究电子杂志，2015，4(5):251-255.
|
| [30] |
Satirapoj B, Adler SG. The Prevalence and management of diabetic nephropathy in western countries [J]．Kidney Dis, 2015, 1(1):61-70.
|
| [31] |
Bomback AS, Kashirasagar AV, Amamoo MA, et al. Change in proteinuria after adding aldosterone blockers to ACE inhibitors angiotensin receptor blockers in CKD: a systematic review [J]. Am J Kidney Dis, 2008, 51(2):199-211.
|
| [32] |
Takahashi S, Katada J, Daida H，et al.Effects of mineralocorticoid receptor antagonists in patient with hypertension and diabetes mellitus：a systematic review and meta-analysis[J]．J Hum Hypertens，2016，30(9):534-542.
|
| [33] |
Bakris GL, Agarwal R, Chan JC, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial [J]. JAMA, 2015, 314(9):884-894.
|
| [34] |
Sirtori CR. The pharmacology of statins [J]. Pharmacol Res, 2014, 88:3-11.
|
| [35] |
Sternlicht H, Bakris GL. Management of hypertension in diabetic nephropathy: howlow should we go? [J]. Blood Purif, 2016, 41(1-3):139-143.
|
| [36] |
Tomino Y, Gohda T. The prevalence and management of diabetic nephropathy in Asia [J]. Kidney Dis, 2015, 1(1):52–60.
|
| [37] |
赵娟，戴助．糖尿病肾病的药物治疗进展[J]．医药导报，2017，36(1):60-63.
|
| [38] |
Batlle D, Wysocki J, Soler MJ, et al. Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy [J]. Kidney Int, 2012, 81(6):520-528.
|
| [39] |
Skov J, Pedersen M, Holst JJ, et al. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial [J]. Diabetes Obes Metab, 2016, 18(6):581-589.
|
| [40] |
Hamza AH, AlBishri WM, Damiati LA，et al. Mesenchymal stem cells: a future experiment exploration for recession of diabetic nephropathy [J]. Ren Fail, 2017, 39(1):67-76.
|
| [41] |
Peired AJ, Sisti A, Romagnani P. Renal cancer stem cells: characterization and targeted therapies [J]. Stem Cells Int, 2016, 5(15):1-12.
|
| [42] |
Jia Z, Sun Y, Yang G, et al. New insights into the PPARγ agonists for the treatment of diabetic nephropathy [J]. PPAR Res, 2014, 1(29):1-7.
|
| [43] |
Komers R, Rho kinase inhibition in diabetic kidney disease [J]. Br J Clin Pharmcol, 2013, 76(4):551-559.
|
| [44] |
Rahimi A, Liaw ST, Taggart J, et al. Validating an ontology-based algorithm to identify patients with type2 diabetes mellitus in electronic health records [J]. Int J Med Inform, 2014, 83(10):768-778.
|
| [45] |
朴春红，李想，霍越，等. 糖基化终末产物抑制剂对糖尿病并发症影响的研究进展[J]．食品科技，2017，42(7):60-65.
|
| [46] |
Liu X, Liu L, Chen P, et al. Clinical trials of traditional Chinese medicine in the treatment of diabetic nephropathy-a systematic review based on a subgroup analysis [J]. J Ethnopharmacol, 2014, 151(2):810-819.
|
| [47] |
庄严，刘敏，罗春艳，等．温阳溢气活血化瘀治疗糖尿病肾病IV期临床研究[J]．中国现代药物应用，2017，11(19):182-183.
|